Bell’s Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine

  • Iftikhar H
  • Noor S
  • Masood M
  • et al.
N/ACitations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Coronavirus disease 2019 (COVID-19) has become the fastest-spreading pandemic of the 21st century. Various vaccines have been made available via emergency use authorization. Currently, two mRNA vaccines are being offered internationally, BNT162b2 and mRNA-1273. In randomized trials of these vaccines, the incidence of Bell's palsy in the vaccinated group does not statistically exceed the placebo group. The FDA recommends increased surveillance for Bell's palsy as a potential side effect with the administration of the vaccines among larger populations globally. There have been a few case reports of Bell's palsy associated with mRNA vaccines. Type I interferons have been proposed as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy. Here, we report the case of a 36-year-old previously healthy patient who developed symptoms of Bell's palsy along with left-arm numbness, tingling, and subjective weakness masquerading as a subacute stroke after receiving the second dose of the mRNA-1273 vaccine. CT and MRI of the brain were unremarkable. He was discharged home with a diagnosis of Bell's palsy and improved on follow-up. mRNA COVID-19 vaccines may be considered a risk factor for Bell's palsy.

Cite

CITATION STYLE

APA

Iftikhar, H., Noor, S. M. U., Masood, M., & Bashir, K. (2021). Bell’s Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine. Cureus. https://doi.org/10.7759/cureus.15935

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free